CCL22 and rheumatoid arthritis: SF CD161+/CD39+ EVs increased CCL20 production, SF CD73+/CD39+ EVs increased CCL17 and CCL22 synthesis in RA fibroblasts, whereas SF CD161+/CD39+ EVs increased IL-17 production, and SF CD39+/CD73+ EVs reduced IL-17 and increased IL-10 production in PBMC in RA [40].